Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 6, 2022; 10(34): 12637-12647
Published online Dec 6, 2022. doi: 10.12998/wjcc.v10.i34.12637
Inflammatory myofibroblastic tumor of the central nervous system: A case report
Zhen-Jin Su, Ze-Shang Guo, Heng-Tong Wan, Xin-Yu Hong
Zhen-Jin Su, Ze-Shang Guo, Heng-Tong Wan, Xin-Yu Hong, Department of Neurosurgical Oncology, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Author contributions: Su ZJ, Guo ZS, and Wan HT designed the study, collected and analyzed the data, explained the data, drafted the manuscript, and performed the literature review; Hong XY performed the surgery and contributed to preoperative and postoperative imaging and analysis and interpretation of pathological and immunohistochemical results; Su ZJ revised the language of the manuscript and made critical revisions to finalize the version submitted; Hong XY provided critical expertise, approved the submitted article, and agreed to be responsible for all aspects of the work; All authors made read and approved the submitted version.
Informed consent statement: Informed written consent was obtained from the patient and her family for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Yu Hong, PhD, Neurosurgeon, Professor, Department of Neurosurgical Oncology, The First Hospital of Jilin University, No. 71, Xinmin Street, Changchun City, Changchun 130000, Jilin Province, China. hongxy@jlu.edu.cn
Received: June 30, 2022
Peer-review started: June 30, 2022
First decision: August 4, 2022
Revised: September 16, 2022
Accepted: November 7, 2022
Article in press: November 7, 2022
Published online: December 6, 2022
Processing time: 154 Days and 22 Hours
Core Tip

Core Tip: Inflammatory myofibroblastic tumors (IMTs) rarely occur in the central nervous system (CNS), and the pathogenesis of IMT-CNS is unknown. We present a 67-year-old woman with IMT-CNS who presented with an exophthalmic protrusion and double vision in the left eye lasting for 3 mo. A 2.4 cm × 1.3 cm mass was found by magnetic resonance imaging at the left anterior cranial fossa base, and postoperative pathology indicated an IMT. Histological, immunohistochemical, and genetic analyses indicated that the IMT-CNS pathogenesis may be autoimmunity related. The main treatments for INT-CNS are gross tumor resection or rituximab infusion combined with high-dose prednisone.